Literature DB >> 22682140

The protein C pathway in cancer metastasis.

C Arnold Spek1, Valder R Arruda.   

Abstract

Cancer is frequently associated with activation of blood coagulation, which in turn has been suggested to promote tumor growth and metastasis. Indeed, low molecular weight heparin treatment significantly prolongs the survival of a wide variety of patients with cancer. Based on this notion that anticoagulant treatment seems to benefit cancer patients, recent experiments aimed to elucidate the importance of the natural anticoagulant protein C pathways in cancer progression. Interestingly, these experiments showed that the repeated administration of exogenous activated protein C limits cancer cell extravasation in experimental animal models. In line, reducing endogenous activated protein C activity dramatically increased the number of experimental metastasis. These data thus strongly suggest that exogenous activated protein C administration may be a novel therapeutic avenue to limit cancer metastasis thereby prolonging overall survival of cancer patients. The current review provides an overview of recent data on the role of the protein C pathway in cancer metastasis. It discusses the potential of activated protein C as a novel target to reduce cancer progression, it points to several limitations of activated protein C administration in the setting of cancer cell metastasis and it suggest zymogen protein C as an attractive alternative.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22682140     DOI: 10.1016/S0049-3848(12)70022-1

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  9 in total

1.  Identification of multipotent mammary stem cells by protein C receptor expression.

Authors:  Daisong Wang; Cheguo Cai; Xiaobing Dong; Qing Cissy Yu; Xiao-Ou Zhang; Li Yang; Yi Arial Zeng
Journal:  Nature       Date:  2014-10-19       Impact factor: 49.962

Review 2.  Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway.

Authors:  E A M Bouwens; F Stavenuiter; L O Mosnier
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

3.  Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis.

Authors:  A J Tafur; G Dale; M Cherry; J D Wren; A S Mansfield; P Comp; S Rathbun; J A Stoner
Journal:  Thromb Res       Date:  2015-10-08       Impact factor: 3.944

4.  Effect of Huisheng oral solution on coagulation function in perioperative period in patients with primary lung cancer.

Authors:  Xiaoguang Yang; Helin Zhang; Fanyi Kong; Guochen Wang; Qianyu Gu; Zheng Zhao; Tiezhi Li; Mingming Ren; Zuosheng Li; Yang Guo
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

5.  Thrombomodulin modulates cell migration in human melanoma cell lines.

Authors:  Andreia da Silva de Oliveira; Likiu Yang; Juliana Echevarria-Lima; Robson Q Monteiro; Alireza R Rezaie
Journal:  Melanoma Res       Date:  2014-02       Impact factor: 3.599

6.  Discovery of significant pathways in breast cancer metastasis via module extraction and comparison.

Authors:  Xiaochen Wang; Huajie Qian; Shuqin Zhang
Journal:  IET Syst Biol       Date:  2014-04       Impact factor: 1.615

7.  TFPI1 mediates resistance to doxorubicin in breast cancer cells by inducing a hypoxic-like response.

Authors:  Gerald F Davies; Arnie Berg; Spike D L Postnikoff; Heather L Wilson; Terra G Arnason; Anthony Kusalik; Troy A A Harkness
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

Review 8.  Distinctive properties of metastasis-initiating cells.

Authors:  Toni Celià-Terrassa; Yibin Kang
Journal:  Genes Dev       Date:  2016-04-15       Impact factor: 11.361

9.  Machine Learning analysis of high-grade serous ovarian cancer proteomic dataset reveals novel candidate biomarkers.

Authors:  Federica Farinella; Mario Merone; Luca Bacco; Adriano Capirchio; Massimo Ciccozzi; Daniele Caligiore
Journal:  Sci Rep       Date:  2022-02-23       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.